Physician profile
Robert Anolik
NPI 1497758536
$60,252.30
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,930 · 2020: $8,208 · 2021: $9,362 · 2022: $26K · 2023: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,175 · Consulting Fee: $5,400 · Travel and Lodging: $814 · Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,175.00 |
| Consulting Fee | $5,400.00 |
| Travel and Lodging | $813.85 |
| Food and Beverage | $138.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49,994.14 | 2019-2023 | Nucala |
| Genentech USA, INC. | $6,676.88 | 2019-2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $2,441.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $514.22 | 2019-2023 | Fasenra |
| Alk-Abello, INC | $178.77 | 2019 | |
| Kaleo, INC. | $112.24 | 2019-2021 | |
| Genzyme Corporation | $102.63 | 2019-2020 | |
| Octapharma USA, INC. | $46.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.73 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.95 | 2020 | |
| Merck Sharp & Dohme LLC | $31.65 | 2019 | |
| Aimmune Therapeutics, INC. | $18.72 | 2021 | |
| Shire North American Group INC | $17.30 | 2019 | |
| Csl Behring | $16.78 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.05 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Anolik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.